Lungpacer Medical
PrivateLast Round
Convertible Debt
Apr 28, 2026
Total Funding Raised
$163.86M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Lungpacer Medical is a medical device company that develops minimally invasive neurostimulation technologies to help critically ill patients wean off mechanical ventilation and restore diaphragm strength.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lungpacer Medical Comparables
Compare Lungpacer Medical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synapse Biomedical Inc. | 90% | |
| Stimdia Medical | 88% | |
| Liberate Medical | 86% |
Lungpacer Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Apr 28, 2026 | ||||
| Growth Equity | Jun 26, 2025 | ||||
| Convertible Debt | Apr 1, 2025 | ||||
| Grant | May 1, 2023 | ||||
| Series B | Apr 6, 2022 | ||||
Growth Equity | Jan 6, 2021 |
Key People
Founding team and executive leadership
Lungpacer Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Canadian Institutes of Health Research | Grant |
| Defense Health Agency | Grant |
| Keiretsu Forum | Angel |
| New Enterprise Associates (NEA) | Private Equity |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Natural Sciences and Engineering Research Council of Canada | Grant |
| Keiretsu Capital | Angel |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
$12M raised in Seed Round.
- Apr 1, 2025
$10M raised from WJFS
Recent news
Latest coverage and updates
- is_developingAug 26, 2026
Lungpacer Medical Inc. is developing diaphragm stimulation system on Dec 1st '24.
- receives_awardAug 19, 2026
Lungpacer Medical Inc. received award 2026 Prix Galien USA Award for Best Medical Technology at Prix Galien USA Awards Ceremony on Aug 19th '26.
Lungpacer Medical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Lungpacer Medical's valuation, stock price, and market status.
Is Lungpacer a public or private company?
Lungpacer is a private company.
What is the current stock price of Lungpacer?
Lungpacer is a private company with no public stock price. No recent secondary market data is available.
How much is Lungpacer worth (valuation)?
Valuation information for Lungpacer is not publicly available.
Can I buy Lungpacer stock?
Lungpacer shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Lungpacer's last funding round?
Lungpacer's most recent funding round was Convertible Debt on April 28, 2026.
Who are the main investors in Lungpacer?
Key investors in Lungpacer include Public Health Emergency Medical Countermeasures Enterprise, Biomedical Advanced Research and Development Authority (BARDA).
Will Lungpacer IPO soon?
No public IPO plans have been announced for Lungpacer.
How can I track Lungpacer secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Lungpacer's secondary market activity and sign up for updates.